Floatz logo

149 assets in Primary Peritoneal Carcinoma

Therapeutic assets addressing Primary Peritoneal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
sl-172154
Primary Peritoneal Carcinoma
Shattuck Labs, Inc.P1CCC (50)
Autologous Natural Killer Cell-Like Ctls
Primary Peritoneal Carcinoma
Roswell Park Cancer InstituteP1/2CCC (48)
Tocilizumab
Primary Peritoneal Carcinoma
Regeneron PharmaceuticalsP1/2CCC (48)
Avb-001
Primary Peritoneal Carcinoma
Avenge Bio, IncP1/2CC (47)
Tilt-123
Primary Peritoneal Carcinoma
TILT Biotherapeutics Ltd.P1/2CC (47)
Tolinapant
Primary Peritoneal Carcinoma
National Cancer Institute (NCI)P1/2CC (47)
Mirvetuximab
Primary Peritoneal Carcinoma
Shattuck Labs, Inc.P1CC (46)
Pamiparib
Primary Peritoneal Carcinoma
Sun Yat-sen UniversityP1/2CC (46)
Surufatinib
Primary Peritoneal Carcinoma
Sun Yat-sen UniversityP1/2CC (46)
23me-00610
Primary Peritoneal Carcinoma
23andMe, Inc.P1/2CC (45)
Deoxycholic Acid
Primary Peritoneal Carcinoma
THERAPIM PTY LTDP1/2CC (45)
Dordaviprone
Primary Peritoneal Carcinoma
Ira WinerP2CC (45)
Dual-Target Car-Nk Cell Product
Primary Peritoneal Carcinoma
Beijing BiotechP1/2CC (45)
Immunoglobulin G1 [240-Alanine,241-Alanine], Anti-(Human Folate Receptor ?) (Human Monoclonal Pro1184 ?1-Chain, Complex With Human Monoclonal Pro1184 ?-Chain, Dimer, 214??,214???,226,226?,232,232?,235,235?-Octakis(Thioether) With N6-[39-[Bis(1-Deoxy-D-Glucitol-1-Yl)Amino]-1-Oxo-4,7,10,13,16,19,22,25,28,31,34,37-Dodecaoxanonatriacont-1-Yl]-N2-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]-L-Lysyl-L-Valyl-N5-(Aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]Carbonyl]Oxy]Methyl]Phenyl]-L-Ornithinamide
Primary Peritoneal Carcinoma
GenmabP1/2CC (45)
Tuvonralimab
Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology GroupP1/2CC (45)
Cdx-585
Primary Peritoneal Carcinoma
Celldex TherapeuticsP1CC (44)
Alnodesertib
Primary Peritoneal Carcinoma
Artios Pharma LtdP1/2CC (43)
Autologous Muc1-Activated T-Cells
Primary Peritoneal Carcinoma
Mayo ClinicP1CC (43)
Avzo-021
Primary Peritoneal Carcinoma
Avenzo Therapeutics, Inc.P1/2CC (43)
azd5335
Primary Peritoneal Carcinoma
AstraZenecaP1CC (43)
bat8006 for
Primary Peritoneal Carcinoma
Bio-Thera SolutionsP1/2CC (43)
Bendamustine
Primary Peritoneal Carcinoma
Mayo ClinicP1CC (43)
Elimusertib
Primary Peritoneal Carcinoma
National Cancer Institute (NCI)P1CC (43)
ft536
Primary Peritoneal Carcinoma
Masonic Cancer Center, University of MinnesotaP1CC (43)
Immunoglobulin G1 [188,412-Bis[4-(Azidomethyl)-L-Phenylalanine]], Anti-(Human Folate Receptor ?) (Human-Mus Musculus Monoclonal Sp8166 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Sp8166 ?-Chain, Dimer, Click Reaction Product With 3-[[[[4-[[N-[4-(11,12-Didehydrodibenz[B,F]Azocin-5(6H)-Yl)-1,4-Dioxobutyl]-L-Valyl-N5-(Aminocarbonyl)-L-Ornithyl]Amino]Phenyl]Methoxy]Carbonyl]Amino]-N,?,?-Trimethyl-L-Phenylalanyl-N-[(1S,2E)-3-Carboxy-1-(1-Methylethyl)-2-Buten-1-Yl]-N,3-Dimethyl-L-Valinamide (1:4)
Primary Peritoneal Carcinoma
Sutro Biopharma, Inc.P1CC (43)
Immunoglobulin G4 [237-Proline,242-Proline,243-Valine,244-Alanine,De-245-Glycine], Anti-(Human Mucin-16) (Human Monoclonal Regn5668 ?4-Chain), Disulfide With Human Monoclonal Regn5668 ?-Chain, (235?228?),(238?231?)-Bis(Disulfide) With Immunoglobulin G4 [230-Proline,235-Proline,236-Valine,237-Alanine,De-238-Glycine,436-Arginine,437-Phenylalanine,446-Proline] Anti-(Human Cd28 Antigen) (Human Monoclonal Regn5668 ?4-Chain) Disulfide With Human Monoclonal Regn5668 ?-Chain
Primary Peritoneal Carcinoma
Regeneron PharmaceuticalsP1/2CC (43)
Itraconazole
Primary Peritoneal Carcinoma
AstraZenecaP1CC (43)
Mdna11
Primary Peritoneal Carcinoma
Medicenna Therapeutics, Inc.P1/2CC (43)
mt027 car-t cells
Primary Peritoneal Carcinoma
Zhejiang UniversityP1CC (43)
Pelcitoclax
Primary Peritoneal Carcinoma
National Cancer Institute (NCI)P1CC (43)
Prgn-3005 Ultracar-T Cells
Primary Peritoneal Carcinoma
Precigen, IncP1CC (43)
27T51
Primary Peritoneal Carcinoma
Regeneron PharmaceuticalsP1CC (41)
ai-061
Primary Peritoneal Carcinoma
OncoC4, Inc.P1CC (41)
Capivasertib
Primary Peritoneal Carcinoma
M.D. Anderson Cancer CenterP1CC (41)
Fludeoxyglucose
Primary Peritoneal Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (41)
Genetically Engineered Ny-Eso-1-Specific T Lymphocytes
Primary Peritoneal Carcinoma
Roswell Park Cancer InstituteP1CC (41)
lyl797
Primary Peritoneal Carcinoma
Lyell Immunopharma, Inc.P1CC (41)
Sapanisertib
Primary Peritoneal Carcinoma
National Cancer Institute (NCI)P1CC (41)
Sovilnesib
Primary Peritoneal Carcinoma
Volastra Therapeutics, Inc.P1CC (41)
Vistusertib
Primary Peritoneal Carcinoma
M.D. Anderson Cancer CenterP1CC (41)
1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer
Primary Peritoneal Carcinoma
PfizerP1/2CC (40)
Cirtuvivint
Primary Peritoneal Carcinoma
University of Colorado, DenverP1C (39)
Monoclonal Antibody Trk-950
Primary Peritoneal Carcinoma
Toray Industries, IncP1C (39)
Re-Stimulated Tumor-Infiltrating Lymphocytes
Primary Peritoneal Carcinoma
University Health Network, TorontoP1C (39)
Alpha-Type-1 Polarized Dendritic Cells
Primary Peritoneal Carcinoma
Roswell Park Cancer InstituteP1/2C (34)
Etodolac
Primary Peritoneal Carcinoma
Memorial Sloan Kettering Cancer CenterN/AD (30)
Luveltamab Tazevibulin
Primary Peritoneal Carcinoma
Sutro Biopharma, Inc.P2/3D (30)
Imgn151
Primary Peritoneal Carcinoma
AbbVieP2NR ()
rp12146
Primary Peritoneal Carcinoma
Rhizen Pharmaceuticals SAP1NR ()
Showing 101 to 149 of 149 assets
PreviousPage 3 of 3Next